Ordenar

Buscar

27/05/2026 Pembrolizumab-Associated Polyserositis with Eosinophilic Pleural Effusion During Adjuvant Therapy for Clear Cell Renal Cell Carcinoma: A Case Report and Targeted Review
Portu, M, Sanz-Beltran, J, Borges, MAD, Navarro, J, Arias, A, Alvarez, P, Fernández-Rebollo, A, Reyes, C, Flores, J, Anguera, G, Maroto, P. Pembrolizumab-Associated Polyserositis with Eosinophilic Pleural Effusion During Adjuvant Therapy for Clear Cell Renal Cell Carcinoma: A Case Report and Targeted Review. Current Oncology. 2026; 33(6)DOI:10.3390/curroncol33060314. PMID:42346214. IF:3.400(Q2/4D).
26/05/2026 Identification of prognostic biomarkers in a large cohort of patients with LGMD R2
Bolano-Diaz, CF, Verdu-Diaz, J, Hao, D, James, MK, Rufibach, L, Blamire, A, Reyngoudt, H, Carlier, PG, Gordish-Dressman, H, Hilsden, H, Spuler, S, Day, J, Jones, KJ, Bharucha-Goebel, D, Pestronk, A, Walter, MC, Paradas, C, Stojkovic, T, Mori-Yoshimura, M, Bravver, E, Pegoraro, E, Mendell, J, Straub, V, Diaz-Manera, J. Identification of prognostic biomarkers in a large cohort of patients with LGMD R2. JOURNAL OF NEUROLOGY. 2026; 273(6)DOI:10.1007/s00415-026-13868-0. PMID:42189263. IF:4.600(Q1/2D).
26/05/2026 Outcomes of Pneumonia in ICUs in Low- and Middle-Income Countries - A Systematic Review
Pitrowsky, M, Pacheco, MB, Ranzani, O, Amado, FS, Nassar, AP Jr, Besen, BAMP, Moralez, GM, Martins, G, Povoa, P, Silva, JRLE, Salluh, JIF. Outcomes of Pneumonia in ICUs in Low- and Middle-Income Countries - A Systematic Review. Nejm Evidence. 2026; 5(6)DOI:10.1056/EVIDoa2500244. PMID:42189048. IF:(Q/D).
25/05/2026 Percutaneous Annuloplasty Followed by TEER for Tricuspid Regurgitation A Multicenter Experience
Ruberti, A, Cepas-Guillén, P, Praz, F, Rudolph, V, Sanchez-Recalde, A, Vilalta, V, Papadis, A, Angellotti, D, Santaló-Corcoy, M, Sanchis, L, Freixa, X. Percutaneous Annuloplasty Followed by TEER for Tricuspid Regurgitation A Multicenter Experience. JACC-Cardiovascular Interventions. 2026; 19(10)DOI:10.1016/j.jcin.2026.02.022. PMID:42191324. IF:11.400(Q1/1D).